Anna Money
Family · Nashville, GANPI 1578968467
Payments from drug & device makers
Across 145 payments — averaging $15.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$918
- GSK$335
- Dexcom, Inc.$147
- Lilly USA, LLC$132
- AstraZeneca$125
- Bayer$69
- plus $546 from 16 others
What the payments were for
- Food & beverage$2,272100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 68 | $918 |
| GSK | 18 | $335 |
| Dexcom, Inc. | 8 | $147 |
| Lilly USA, LLC | 8 | $132 |
| AstraZeneca | 8 | $125 |
| Bayer | 4 | $69 |
| Idorsia Pharmaceuticals US Inc | 4 | $68 |
| Amgen | 4 | $64 |
| Novo Nordisk | 3 | $63 |
| Boehringer Ingelheim | 4 | $61 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $54 |
| Teva Pharmaceuticals USA, Inc. | 2 | $48 |
| Merck | 3 | $37 |
| Abbott | 1 | $25 |
| Novartis | 1 | $23 |
| Astellas Pharma US Inc | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| Exact Sciences | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
| Pfizer | 1 | $12 |
How this compares
$2,272 in reported general payments places this provider in the 80th percentile of 6,258 family providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 72 | $83,241 |
| OzempicSemaglutide | 84 | $78,987 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 63 | $52,234 |
| LinzessLinaclotide | 28 | $29,455 |
| JardianceEmpagliflozin | 34 | $23,938 |
| TrulicityDulaglutide | 14 | $13,769 |
| MyrbetriqMirabegron | 22 | $12,340 |
| VraylarCariprazine Hcl | 11 | $9,261 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $7,450 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $6,242 |
| Atrovent HfaIpratropium Bromide | 11 | $5,319 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 79 | $2,017 |
| Gabapentin | 153 | $1,862 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $1,007 |
| Vilazodone Hcl | 12 | $991 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $132 | $97,01086 claims |
| Novo NordiskOzempic | $63 | $78,98784 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $335 | $58,47574 claims |
| AbbVieLinzess, Vraylar, Synthroid | $918 | $39,59659 claims |
| Boehringer IngelheimJardiance | $61 | $23,93834 claims |
| Astellas Pharma US IncMyrbetriq | $20 | $12,34022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,258 family providers in Georgia.
Other family in Nashville
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
- Jessica FeehanCanton$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.